Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
RIGL
STRONG BUYAPPROVERigel Pharmaceuticals, Inc. · Healthcare · United States · $680M · Avg Vol: $15M/d
Rigel Pharmaceuticals has moved from development-stage to a commercial haematology and oncology portfolio and reached sustained profitability, which is consistent with its strong quality score (Q82). Forward-EPS consensus has been revised up 4.3% and the trivial insider selling (0.03% of shares outstanding) reads as routine plan activity. No accounting, distress or governance issue is known.
COMPANY DESCRIPTION
Rigel Pharmaceuticals, Inc. is a commercial-stage biotechnology company dedicated to the discovery, development, and provision of novel small molecule drugs for serious diseases. Its approved product, TAVALISSE, is used to treat chronic immune thrombocytopenia, showcasing its expertise in immunology. Rigel maintains a competitive edge through its proprietary R&D platform and pipeline targeting various immunological and oncological conditions.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 120.2M | 116.9M | 179.3M | 294.3M | 34.8% | 299.8M | 276.6M | 330.9M | 6.0% |
| EPS | -3.40 | -1.44 | 0.99 | 20.40 | 1960.6% | 19.29 | — | — | — |
| Shares | 17.3M | 17.5M | 17.7M | 18.3M | +5.6% | 18.5M | — | — | — |
| Debt | 41.6M | 60.6M | 60.0M | 53.3M | 8.7% | 45.7M | — | — | — |
| Equity | -13.6M | -28.6M | 3.3M | 391.5M | 11806.3% | — | — | — | — |
| Op CF | -73.8M | -5.7M | 31.5M | 75.7M | 140.4% | 79.3M | — | — | — |
| Inv CF | 72.8M | -4.3M | 4.1M | -92.4M | — | — | — | — | — |
| Fin CF | 6.5M | 18.4M | -11.6M | 0.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of RIGL are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| RIGL | Rigel Pharmaceuticals, Inc.(you) | $680M | 98 | STRONG BUY |
| CRMD | CorMedix Inc. | $617M | 98 | STRONG BUY |
| PBYI | Puma Biotechnology, Inc. | $406M | 97 | STRONG BUY |
| QTTB | Q32 Bio Inc. | $450M | 92 | STRONG BUY |
| INVA | Innoviva, Inc. | $1.6B | 97 | STRONG BUY |
| ZVRA | Zevra Therapeutics, Inc. | $563M | 82 | STRONG BUY |
| ABUS | Arbutus Biopharma Corporation | $865M | 81 | STRONG BUY |
| HRMY | Harmony Biosciences Holdings, Inc. | $2.0B | 99 | STRONG BUY |
| MDXG | MiMedx Group, Inc. | $626M | 76 | BUY |
| PLX | Protalix BioTherapeutics, Inc. | $191M | 99 | STRONG BUY |
Peer medians: ROE -25.6% · P/E 27.7x · Gross margin 50.5%